Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.
Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...
StockStory.org on MSN
Pfizer earnings: What to look for from PFE
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors ...
The pharmaceutical giant just extended the lifespan of one of its top drugs.
April 28 (Reuters) - Pfizer said on Tuesday it has settled patent disputes with three generic drugmakers over its blockbuster ...
By Padmanabhan Ananthan May 1 (Reuters) - The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' breast ...
Hosted on MSN
Pfizer lags as Cadrenal advances to Phase 3 trial
Pfizer shares remain under pressure amid declining COVID vaccine demand, looming patent expirations, and delays in entering the GLP-1 weight-loss market. Meanwhile, Cadrenal Therapeutics gained ...
Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...
Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...
Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...
The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results